AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316
AiCuris scientist and project leader Dr. Alexander Birkmann will give an overview on the pharmacokinetic-pharmacodynamic relationship of AIC316 by presenting efficacy data from experiments performed in a murine infection model and Phase 1 pharmacokinetic data which demonstrate that the predicted efficacious concentrations of AIC316 will be easily achieved in humans.
“The results also clearly confirm that AIC316 has the potential for once daily dosing which we consider as a prerequisite for the intended indication of genital herpes” said Dr. Holger Zimmermann, Chief Scientific Officer of AiCuris. AiCuris’ CEO Prof. Helga Rübsamen-Schaeff adds: “Genital and labial herpes may be considered as “unimportant” infectious diseases as they are normally self-limiting and there are drugs to treat them. However, we know that patients may suffer tremendously, physically and psychologically and that the unmet medical need is still very high. Therefore we are committed to make a real difference with an innovative and resistance-breaking drug against Herpes simplex."
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.